1	A Novel Methodology to Recalibrate Pathogenic Range of SCA36 Repeat Expansions				
2	for PGT-M				
3	Fulin Liu ¹ , Wen Huang ¹ , Ling Liao [*] , Jiyun Yang [*]				
4	Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Gene				
5	tics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan				
6	Provincial People's Hospital, University of Electronic Science and Technology, Chengdu				
7	610072, China				
8					
9	* Corresponding authors:				
10	Email address: <u>yangjiyun@yeah.net</u> (Jiyun Yang), <u>450766957@qq.com</u> (Ling Liao)				
11	¹ These authors contribute equally to this work.				
12					
13	Abstract				
14	Background: Spinocerebellar ataxia-36 (SCA36) is an inherited neurodegenerative disorder				
15	caused by the heterozygous expansion of an intronic GGCCTG hexanucleotide repeat in the				
16	NOP56 gene on chromosome 20p13. Unaffected individuals typically carry 3 to 14 repeats,				
17	whereas affected individuals carry 650 to 2,500. However, based on a single study, this				
18	pathogenic range was conservatively established, limiting its extended clinical applicability				
19	such as preimplantation genetic testing (PGT). In this study, we propose a novel methodology				
20	to recalibrate the pathogenic range of SCA36 repeat expansion.				
21	Methods: We conducted a comprehensive literature review and collected examination data				
22	from 2012 onward. We used the gamma distribution to describe the data distribution and				
23	applied Bayesian methods to update the prior distribution with data from recent publications.				
24	Based on the recalibrated distribution, the 95% confidence interval (CI) was used to				
25	determine the new lower boundary of the pathogenic range. A pedigree was collected to				

validate the proposal with long-read sequencing (LRS) applied to detect the high GC contentand long length of repeat expansions.

28	Results: Our results, based on 2 studies, indicate that the data distribution is well-described
29	by gamma distribution. The prior, likelihood and posterior distributions within the 95% CI
30	for the integrated research of SCA36 pathogenic repeat expansions were [446, $+\infty$), [124,
31	$+\infty$), and [484, $+\infty$), respectively. These recalibrated pathogenic ranges were validated by an
32	authentic case: a proband diagnosed with SCA36 carrying 418 repeats and her daughter with
33	499 repeats, under the detection of LRS.
34	Conclusions: Therefore, we proposed a novel methodology that integrates updated data, 95%
35	CI using Bayesian methods and LRS for accurate detection of repeat expansions of dynamic
36	mutations to present an up-to-date pathogenic range of SCA36, as well as other similar
37	diseases.
38	
39	Keywords: Spinocerebellar ataxia-36; Repeat expansions; Bayesian methods; Confidence
40	interval; Diagnosis; Long-read sequencing; Preimplantation genetic testing
41	
42	Background
43	

The human genome contains a substantial number of tandem repeats (TRs). TRs exhibit a high mutation rate within the genome due to their repetitive nature, resulting in enormous polymorphism and multiallelism. The variability of TRs in the length of the repeat sequences occurs in both non-coding and coding regions of the genome [1]. A certain range of TR expansions beyond a critical threshold can lead to disease onset and may increase or decrease across generations, which is the foundation of dynamic mutations [2]. The intergenerational

50 expansion of dynamic mutations is a well-documented phenomenon that underlies the51 pathogenesis of at least 50 known disorders [3].

52

53 Clinical diagnosis of dynamic mutations necessitates not only the observation of 54 characteristic clinical manifestations but also the application of auxiliary diagnostic tests, 55 with genetic testing being paramount. Diagnosis depends on identifying the number of 56 dynamic mutations within a defined pathogenic range. When the mutation count falls within 57 the defined range, a clinical diagnosis can be made; otherwise, a negative result is inferred. 58 However, there exists an uncertain range of clinical significance beyond the confirmatory and 59 exclusion ranges. Currently, the evaluation of the uncertain range primarily relies on clinical 60 diagnosis. If clinical diagnosis is definitive, the uncertain range is considered positive; if 61 clinical phenotypes cannot be correlated, it is deemed negative. Nonetheless, clinical practice 62 often encounters cases where phenotypes are ambiguous, and genetic testing results fall 63 within the uncertain range. This poses ethical challenges, particularly for preimplantation 64 genetic testing (PGT) candidates, where ethics committees may not approve the subsequent 65 procedure according to the guidelines [4-6].

66

67 PGT, especially PGT for monogenic disorders (PGT-M), aims to enable pregnancies 68 unaffected by specific genetic traits carried by one or both parents. PGT-M offers couples 69 with genetic disorders the opportunity to have their offspring and avoid the birth of defective 70 fetuses, yet its ethical standards are stringently ruled. This stringency stems from the current 71 limitations in basic medical research to fully elucidate the relationship between genetic 72 variants and clinical phenotypes, leading to poor gene-disease mapping. Thus, strict inclusion 73 criteria are employed to minimize off-target resulting in defective fetuses. Namely, PGT-M 74 can be only administered in a certain pathogenic range but not the uncertain range of repeat

expansions, which poses a significant challenge to the uncertainty. Such stringent criteria
may result in too many considerations to perform the PGT-M. Therefore, this study proposes
a novel but reasonable methodology to recalibrate the defined pathogenic range of repeat
expansions so that more patients within the uncertain range win steady support for the PGTM.

80

81 Taking spinocerebellar ataxia type 36 (SCA36) as an example, SCA36 was initially identified 82 in Japanese and Spanish families as a new type of SCA, characterized by late-onset, slowly 83 progressive cerebellar syndrome often involving motor neurons, or accompanied by sensory 84 neural hearing loss, and cognitive, and emotional disturbances [7, 8]. It is caused by a 85 heterozygous expansion of an intronic GGCCTG hexanucleotide repeat in the NOP56 gene 86 on chromosome 20p13. Unaffected individuals carry 3 to 14 repeats, whereas affected 87 individuals have 650 to 2,500 repeats (OMIM #3614153). However, the range was defined 88 based on only one single research [7] under an obsolete technology and unsuitable statistics, 89 making individuals under the uncertain range for SCA36 diagnosis between 14 to 650 repeats 90 inaccessible to PGT-M.

91

92 We recommend an update of knowledge. This study, taking CA36 as an example, aims to 93 integrate updated data, 95% CI under Bayesian methods and long-read sequencing (LRS) to 94 present an up-to-date pathogenic range of SCA36, along with the validation of a specific 95 clinical case, to propose an efficient novel methodology to recalibrate pathogenic repeat 96 expansions.

97

98 Methods

99 **Participants**

100 The study subjects were members of one generation of a Han Chinese ataxia family pedigree 101 in Sichuan province. A detailed medical history and physical examination record of the 102 proband (II-2) and other family members were evaluated by our multidisciplinary teams 103 including a geneticist, neurologist, otorhinolaryngologist, obstetrician, and gynecologist, 104 reproductive endocrinologist, members of the ethical committee. The blood samples were 105 obtained from participants who asked for carrier screening for SCA36 at the Center for 106 Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's 107 Hospital. This study was in agreement with the Guidance of the Ministry of Science and 108 Technology for the Review and Approval of Human Genetic Resources. All study procedures 109 were approved by the Ethical Committee of Sichuan Academy of Medical Sciences & 110 Sichuan Provincial People's Hospital in accordance with the Helsinki Declaration of 1975, as 111 revised in 2000, and patients signed an informed consent form.

112 Repeat-primed PCR

Given the initial suspicion of SCA36, repeat-primed polymerase chain reaction (RP-PCR) screening combined with Southern blotting with capillary electrophoresis was employed to identify the presence of SCA36 in the proband and other family members. RP-PCR utilizes repeat primers that amplify alleles, producing PCR products that anneal and form a "ladder" pattern upon separation by capillary electrophoresis. For DNA fragment analysis, the RP-PCR products were processed using the ABI-Prism 3730XL Genetic Analyzer, and the resulting data were analyzed with GeneMarker software.

120 Targeted gene capture and PacBio long-read Sequencing

121 Using a g-tube tube (Covaris, Australia) and centrifugation at $6000 \times g$, 3 µg of genomic 122 DNA was physically sheared into 8-9 kb fragments after the purity, followed by the 123 evaluation of the integrity of the DNA. The DNA fragments were then connected with 124 barcodes after being repaired by the Damage Repair End Preparation Mix (Vazyme, China). 125 Subsequently, Rapid DNA ligase (Vazyme, China) was used to attach adapters to the DNA 126 fragments. After purifying the ligation products with Agencourt AMPure XP beads 127 (Beckman Coulter, USA), amplification was carried out. The amplified products were 128 captured by hybridization with biotinylated probes (Boke Bioscience, China) that targeted 129 genes relevant to repeat expansion diseases. The SMRTbell Express Template Kit 2.0 130 (PacBio, USA) was utilized to generate an SMRTbell library. The constructed DNA library 131 was then subjected to long-read sequencing on the PacBio Sequel IIe platform.

132 After the sequencing data was evaluated and qualified by SMRT Link, bioinformatics 133 analysis of the raw sequencing data was carried out. The particular processes are as follows. 134 The raw sequencing data was analyzed using the official PacBio software package SMRT 135 Link (version 12.0) to generate HiFi reads, and CCS (Circular Consensus Sequence) reads 136 were also automatically generated by the PacBio SMRT Analysis Module, which is an apart 137 of SMRT Link. The data of each sample was divided according to the barcode using the Lima 138 software (version 2.7.1). The CCS reads were aligned to the reference genome GRCh37/hg19 139 using the Minimap2 software (version 2.24), and the number of repeat units of the gene was 140 calculated using GrandSTR, while the number of repeat units on each read was manually 141 checked using the IGV software.

142 Statistical analysis

144 Considering unaffected individuals typically carry 3 to 14 repeats, whereas affected 145 individuals carry 650 to 2,500 repeats, the pathogenic repeats exhibit a pronounced skewed 146 distribution with one tail. Gamma distribution was hence adopted to describe the pathogenic 147 repeat range. Based on this assumption, we first estimated the prior distribution based on the 148 dataset from [7].

150
$$Prior: gamma(\kappa|s,r) = \left(\frac{r^s}{\Gamma(s)}\right) \kappa^{s-1} e^{-rk},$$

151

152 where κ is a shape parameter, *s* is a scale parameter and *r*, called a rate parameter, is an 153 inverse scale parameter r = 1/s. κ and *s* are calculated based on the mean and variance of 154 the old data.

155 Bayesian approaches were applied to update this posterior probability, based on the prior 156 probability and new data. Given two events A and B, the conditional probability of A given 157 that B is true is expressed as follows:

$$P(A|B) = P(B|A)P(A)/P(B)$$

where P(A) is the prior probability of A to present the experience, P(B|A) is the likelihood function to present the new data, P(A|B) is posterior probability to present the current knowledge, and P(B) is the total probability of the probability of B with $P(B) \neq 0$. As P(B)

161 does not change in the same analysis, the formula can be also interpreted as:

$$P(A|B) \propto P(B|A)P(A)$$

162 where the current knowledge is proportional to the product of the likelihood function and the

163 new data under the same data distribution. Assume that the new observed dataset consists of

164 *n* observations, denoted as $x_1, x_2, ..., x_n$. Assuming a conjugate prior of the same distribution,

165 the posterior distribution also follows a gamma distribution with updated parameters:

$$s_{new} = s + ns_0$$

167

$$k_{new} = k + \sum_{i=1}^{n} x_i$$

169 where s_0 is estimated by the likelihood from the new data [9]. The posterior distribution is 170 then given by:

171

Post:
$$gamma(k_{new}|s_{new}, r_{new}) = \left(\frac{r_{new}}{\Gamma(s_{new})}\right)k_{new}s_{new}s_{new} e^{-r_{new}k_{new}}$$

172

173 where $r_{new} = 1/s_{new}$. Using this distribution, we calculated a 95% confidence interval (CI) 174 to estimate the range within which the true population parameter is expected to fall with high 175 confidence. This range also defines the new cutoff for normal observations, classifying 176 patients with repeats falling within this range as having the presence of SCA36. Data were 177 analyzed and visualized with R statistical software (v4.2.1; R Core Team 2023)[10].

178

179 Results

180

181 1 Literature review and summary

182

183 We conducted a comprehensive search with the keywords "SCA36" or "Spinocerebellar 184 ataxia-36" across several databases, including PubMed, Embase, Web of Science, and 185 additional platforms such as Dimensions and Semantic Scholar in May 2024, yielding a total 186 of 67 articles. The subsequent filter process is illustrated in Figure 1. To elaborate, we first 187 refined our search publication date from 2012 onwards to include literature published after 188 the research from which the pathogenic range of SCA36 was defined, retaining 55 records. 189 We then meticulously reviewed the abstracts of these articles, excluding 9 duplicates, 11 190 reviews, 18 basic medical research, 2 case reports, 7 comments, and 2 non-biomedical

191 articles. The remaining 9 articles encompassed detailed data and processing methodologies. 192 Accordingly, Table 1 summarizes these 9 articles, detailing the authors, publication year, 193 ethnic group, sample size, repeat range, mean age at onset, detection method, and references. 194 Upon a thorough examination of the original data from these 9 articles [7, 9, 11-17], we 195 noticed issues such as insufficient data [11-13], questionable data reliability [14], suboptimal 196 data distribution [11], and poor data accessibility [15, 16], and non-Caucasian ethical 197 population [11-14]. Consequently, we determined that only two articles provided data 198 suitable for subsequent analysis [7, 9].

199

200 2 Recalibrating pathogenic range of SCA36 repeat expansions

201

202 According to the data published in 2012 by Garcia-Murias et al [7], which Online Mendelian 203 Inheritance in Man (OMIM, https://www.omim.org/) used as a guide, the range of pathogenic 204 repeat expansions is 650 to 2,500. By examining the original data, we found it skewed and 205 inconsistent with the normal distribution. Taking the one-tailed and skewed distribution of 206 the data into consideration, we employed the gamma distribution to simulate the prior 207 distribution, obtaining a 95% CI of [446, $+\infty$]. Since the prior distribution data shares a 208 common original disease with the data published in 2014 by Obayashi et al.[9] we defined 209 them as conjugate distributions. Therefore, we simulated the likelihood function, obtaining a 210 95% CI of [124, $+\infty$]. Using Bayesian methods, we inferred the posterior distribution and its 211 95% CI of [484, $+\infty$]. The fitted distribution curves and the integrated curve are depicted in 212 Figure 2. The results indicate that the lower bound of the pathogenic repeat expansions in the 213 posterior distribution is 484, which is less than the 650 as defined in the OMIM guidelines.

214

215 3 Case validation

216

217 In this study, the proband (II-2) initially presented with progressive symptoms in her 50s, 218 including gait instability, frequent falls, difficulty in lifting the feet, swaying while walking, 219 inability to walk in a straight line, slurred speech, choking on water, dizziness, and slight 220 difficulty in writing. Magnetic resonance imaging indicated cerebellar atrophy (Figure 3B). 221 She did not exhibit bradykinesia, hand tremors, or other Parkinsonian symptoms, and her 222 pain, light touch, and proprioception were intact. Additionally, electromyography did not 223 show significant reductions or the presence of large motor unit potentials. Genetic panel 224 results were negative for SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA12, SCA17, and 225 DRPLA, but revealed that the SCA36 repeats exceeded 14 (Figure 3B). Her daughter (III-1), 226 seeking consultation for assisted reproductive technology, also underwent genetic panel 227 testing, which similarly indicated that the SCA36 repeats exceeded 14 (Supplementary 228 Table_S1). Testing of I-2 was negative, while I-1 was absent due to passing away. Given III-229 1's request for PGT-M, we performed long-read sequencing (LRS) to ascertain the precise 230 repeats. Figure 3B illustrates the span of long reads in LRS for II-2 and III-1. Results 231 revealed that II-2 had 418 repeats, while III-1 had 499 repeats, with other potential disease-232 related gene mutations excluded (Supplementary Table_S2&S3). These findings demonstrate 233 that III-1's repeats fall within the previously mentioned 95% CI of posterior distribution [484, 234 $+\infty$], thus confirming that III-1 meets the criteria for a positive SCA36 diagnosis within the 235 updated pathogenic range of repeat expansion.

236

237 Discussion

238

The ethical standards for PGT-M in SCA36 patients are stringently ruled and confined to acertain pathogenic range. The overcautious criterion has prevented those SCA36 patients

241 within an uncertain range from performing the PGT-M. In this study, we propose a more 242 inclusive and pragmatic diagnostic methodology to encompass more SCA36 patients in the 243 uncertain range. Initially, we conducted a comprehensive literature review, identifying three 244 original studies with accessible data. Subsequently, we employed Bayesian methods to infer 245 the posterior distribution, obtaining a 95% CI for the distribution. Our results indicated that 246 the lower bound fell below the defined pathogenic range. Lastly, we utilized the LRS 247 technology in the clinical practice to identify the pathogenic repeat expansions in a case, 248 whose repeat expansions also fell within the aforementioned 95% CI, thereby validating the 249 necessity and efficacy of recalibration for repeat expansions.

250

251 SCA36 exemplifies cases within an uncertain range that encounter the ambiguity of 252 mutations and phenotypes, displaying an uncertain diagnostic range of 14-650 repeat 253 expansions, within which patients may not exhibit pronounced symptoms, particularly those 254 of childbearing age who have not reached the average onset age of 51.23 ± 7.33 years (male 255 = 51.23 years, female = 51 years) [11]. In our case, III-1 is in her 30s, suggesting that she is 256 likely far from the average age of disease onset. However, SCA36, as a dominant repeat 257 expansion disorder, is characterized by genetic anticipation, where clinical manifestations 258 appear earlier and/or become more severe in successive generations. Dominant repeat 259 expansion disorders have a well-established correlation between expansion size and both age 260 of onset and disease severity, with larger expansions associated with earlier onset and more 261 severe phenotypes [18]. Compared to II-2's 418 repeats, that III-1 has 499 repeats suggests 262 III-1 might experience earlier onset and more severe symptoms than II-2. To prevent the 263 transmission and exacerbation of the serious condition to her children, the application of 264 PGT-M in assisted reproductive technology is highly warranted.

266 While the stringent rules for PGT-M in assisted reproductive technology are 267 understandable—primarily aimed at avoiding potential off-targets, especially for monogenic 268 diseases of unknown etiology-such stringent criteria may not be appropriate for the 269 uncertain definition of dynamic mutations. Taking SCA36 into consideration, PGT-M is only 270 permissible when repeat expansions exceed 650. Nevertheless, in our case, both II-2 (with 271 typical manifestations) and III-1 fall below the range. Therefore, it is reasonable to suggest 272 that the defined pathogenic range should be extended more rationally to enhance the 273 application of PGT-M in clinical practice. In this study, the Bayesian methods, along with 95% 274 CI were applied to recalibrate the pathogenic range. Bayesian theorem allows for the 275 integration of prior experience with updated data, produced by new research or novel 276 technologies, to refresh the current knowledge [19]. Thus, an effective method to integrate 277 past and future data is highly beneficial for updating clinical diagnostic guidelines. In our 278 case, the defined pathogenic range of 650 to 2,500 was based on the single research from [7], 279 but with our recalibration based on Bayesian methods the updated range is [484, $+\infty$]. III-1's 280 repeat expansion therefore falls in, meeting the ethical requirements for PGT-M in assisted 281 reproductive technology. Indeed, we have also conducted a direct integration of the datasets 282 from the two aforementioned studies, yielding a 95% CI of [337, $+\infty$] (Supplementary 283 Figure_S1), which agreed with the conclusion but might undertake the potential 284 overshadowing of information and weight bias from smaller datasets by those with larger 285 sample sizes. Therefore, we advocate for the application of Bayesian methods, which 286 amalgamates prior and likelihood function data, to refine and enhance the integral 287 understanding.

288

It is important to note that SCA36 is characterized by a heterozygous expansion of an intronicGGCCTG hexanucleotide repeat in the NOP56 gene, resulting in high GC content and

291 extremely long repeat motifs in the repeat expansion [7, 8]. Conventional detection methods 292 are limited. In our case, the patient initially underwent RP-PCR combined with Southern 293 blotting following capillary electrophoresis to measure the GGCCTG repeat expansions, but 294 specific repeat sequences were not obtained. As a matter of fact, over the past decades, the 295 repetitive nature and abundance of short TRs in the human genome have posed significant 296 challenges for genome-wide studies [18]. Short-read sequencing alone fails to accurately map 297 long repeat sequences, leading to covered reads often mapping to multiple genomic regions, 298 thereby being truncated or discarded. Recently, the LRS has emerged in clinical practice to 299 perform a more precise detection of TR expansions [20]. The LRS can obtain reads 300 exceeding 15 kb and sometimes up to 2 Mb, enabling the detection of thousands of structural 301 variants, including repeat regions, in individuals [21]. In this study, compared to RP-PCR 302 combined with Southern blotting, LRS was used for the accurate detection of dynamic 303 mutations to determine whether the repeat expansions exceeded 14 by considering the high 304 GC content and long length. The LRS technology, with its long-read length, high accuracy, 305 and lack of GC bias, provided more specific repeats, thereby offering crucial assistance in 306 determining whether the repeat expansion falls within the recalibrated pathogenic range.

308 This study has limitations. Firstly, the sample size is limited. We obtained merely 44 patients 309 (27 from the prior and 17 from the likelihood) to recalibrate the pathogenic range. The 310 limited sample size might lead to bias in estimating the true distribution of the data, despite of 311 our attempt to request data from other corresponding authors. Notably, in these limited 312 samples, low repeats between 20 and 30 occurred only in three individuals, casting doubt on 313 whether low repeats were outliers. Fortunately, subsequent cases in Chinese and British 314 cohorts [11, 15] with low repeats reaching 30 or 60 provided proofs to dispute the doubt of 315 the previous data that repeats between 20 to 30 were probably outliers. The second limitation

pertains to ethnic differences. Caucasian participants were included in our work to describe the prior, likelihood, and posterior distributions. However, a Han Chinese pedigree as the clinical practice was adopted to validate the recalibration, which might raise the overestimation or underestimation of the pathogenic range given the diversity of gene variations in different ethical populations [22]. This underscores the necessity for further follow-up studies in Caucasian populations, or alternatively, a retrospective analysis with East Asian population to reassess the conclusions.

323

```
324 Conclusions
```

325

To sum up, we proposed a novel methodology that integrates updated data, 95% CI using Bayesian methods and LRS for accurate detection of repeat expansions of dynamic mutations to present an up-to-date pathogenic range of SCA36. We sincerely hope this work would well serve as a strong evidence for those suffering from an uncertain range of repeat expansion.

330

331 Ethics approval and consent to participate

This study was in agreement with the Guidance of the Ministry of Science and Technology for the Review and Approval of Human Genetic Resources. All study procedures were approved by the Ethical Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital in accordance with the Helsinki Declaration of 1975, as revised in 2000, and patients signed an informed consent form.

337

338 Consent for publication

339 Patients signed a consent form for publication.

341 Availability of data and materials

342 All data are incorporated into the article and its online supplementary material.

343

344 Competing interests

345 The authors declare that they have no conflict of interest.

346

347 Funding

- 348 This study was supported by the Youth Talent Foundation of Sichuan Academy of Medical
- 349 Sciences & Sichuan Provincial People's Hospital (No. 2022QN37), Sichuan Science and
- 350 Technology Program (No. 2023NSFSC1605).

351

352 Authors' contributions

Fulin Liu.: designed the study and wrote the first draft of the manuscript. Wen Huang: participated in the manuscript organization. Ling Liao: supervised the study and edited the first draft of the manuscript. Jiyun Yang: conceived the original idea, and edited the final version of the manuscript.

357

358 Acknowledgements

We thank Beijing GrandOmics Biosciences Co., Ltd. for the technical support on PacBioSMRT target sequencing.

361

362 **References:**

- Fazal S, Danzi MC, Cintra VP, Bis-Brewer DM, Dolzhenko E, Eberle MA, Zuchner S:
 Large scale in silico characterization of repeat expansion variation in human
- **365** genomes. Sci Data 2020, 7:294.

366	2.	Balzano E, Pelliccia F, Giunta S: Genome (in)stability at tandem repeats. Semin

- **367** *Cell Dev Biol* 2021, **113:**97-112.
- 368 3. Depienne C, Mandel JL: 30 years of repeat expansion disorders: What have we
 369 learned and what are the remaining challenges? *Am J Hum Genet* 2021, 108:764370 785.
- 371 4. Yan L, Cao Y, Chen ZJ, Du J, Wang S, Huang H, Huang J, Li R, Liu P, Zhang Z, et al:
 372 Chinese experts' consensus guideline on preimplantation genetic testing of
- 373 monogenic disorders. *Hum Reprod* 2023, **38**:ii3-ii13.
- 374 5. Committee EPCS, Carvalho F, Coonen E, Goossens V, Kokkali G, Rubio C, Meijer-
- 375 Hoogeveen M, Moutou C, Vermeulen N, De Rycke M: ESHRE PGT Consortium
- **good practice recommendations for the organisation of PGT.** *Hum Reprod Open*
- **377** 2020, **2020:**hoaa021.
- 378 6. Ginoza MEC, Isasi R: Regulating Preimplantation Genetic Testing across the
- World: A Comparison of International Policy and Ethical Perspectives. *Cold*Spring Harb Perspect Med 2020, 10.
- 381 7. Garcia-Murias M, Quintans B, Arias M, Seixas AI, Cacheiro P, Tarrio R, Pardo J,
- 382 Millan MJ, Arias-Rivas S, Blanco-Arias P, et al: 'Costa da Morte' ataxia is
- **383** spinocerebellar ataxia 36: clinical and genetic characterization. *Brain* 2012,
- **384 135:**1423-1435.
- 385 8. Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, Habu T, Liu W,
- 386 Okuda H, Koizumi A: Expansion of intronic GGCCTG hexanucleotide repeat in
- 387 NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor
- **388 neuron involvement.** *Am J Hum Genet* 2011, **89:**121-130.
- 389 9. Obayashi M, Stevanin G, Synofzik M, Monin ML, Duyckaerts C, Sato N,
- 390 Streichenberger N, Vighetto A, Desestret V, Tesson C, et al: Spinocerebellar ataxia

391		type 36 exists in diverse populations and can be caused by a short hexanucleotide
392		GGCCTG repeat expansion. J Neurol Neurosurg Psychiatry 2015, 86:986-995.
393	10.	Dessau RB, Pipper CB: ["R"project for statistical computing]. Ugeskr Laeger
394		2008, 170: 328-330.
395	11.	Zou J, Wang F, Gong Z, Wang R, Chen S, Zhang H, Sun R, Gao C, Li W, Shang J,
396		Zhang J: A Chinese SCA36 pedigree analysis of NOP56 expansion region based
397		on long-read sequencing. Front Genet 2023, 14:1110307.
398	12.	Wang Q, Zhang C, Liu S, Liu T, Ni R, Liu X, Zhong P, Wu Q, Xu T, Ke H, et al:
399		Long-read sequencing identified intronic (GGCCTG)n expansion in NOP56 in
400		one SCA36 family and literature review. Clin Neurol Neurosurg 2022, 223:107503.
401	13.	Lee YC, Tsai PC, Guo YC, Hsiao CT, Liu GT, Liao YC, Soong BW:
402		Spinocerebellar ataxia type 36 in the Han Chinese. Neurol Genet 2016, 2:e68.
403	14.	Ikeda Y, Ohta Y, Kobayashi H, Okamoto M, Takamatsu K, Ota T, Manabe Y,
404		Okamoto K, Koizumi A, Abe K: Clinical features of SCA36: a novel
405		spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology 2012,
406		79: 333-341.
407	15.	Lopez S, He F: Spinocerebellar Ataxia 36: From Mutations Toward Therapies.
408		Front Genet 2022, 13:837690.
409	16.	Valera JM, Diaz T, Petty LE, Quintans B, Yanez Z, Boerwinkle E, Muzny D,
410		Akhmedov D, Berdeaux R, Sobrido MJ, et al: Prevalence of spinocerebellar ataxia
411		36 in a US population. Neurol Genet 2017, 3:e174.
412	17.	Zeng S, Zeng J, He M, Zeng X, Zhou Y, Liu Z, Xia K, Pan Q, Jiang H, Shen L, et al:
413		Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China.
414		<i>Clin Genet</i> 2016, 90: 141-148.

415	18.	Chintalaphani SR, Pineda SS, Deveson IW, Kumar KR: An update on the					
416		neurological short tandem repeat expansion disorders and the emergence of					
417		long-read sequencing diagnostics. Acta Neuropathol Commun 2021, 9:98.					
418	19.	Xu H, Wang S, Ma LL, Huang S, Liang L, Liu Q, Liu YY, Liu KD, Tan ZM, Ban H,					
419		et al: Informative priors on fetal fraction increase power of the noninvasive					
420		prenatal screen. Genet Med 2018, 20:817-824.					
421	20.	Tandem repeats in the long-read sequencing era. Nat Rev Genet 2024, 25:449.					
422	21.	van Dijk EL, Naquin D, Gorrichon K, Jaszczyszyn Y, Ouazahrou R, Thermes C,					
423		Hernandez C: Genomics in the long-read sequencing era. Trends Genet 2023,					
424		39: 649-671.					
425	22.	Taylor DJ, Chhetri SB, Tassia MG, Biddanda A, Battle A, McCoy RC: Sources of					
426		gene expression variation in a globally diverse human cohort. <i>bioRxiv</i> 2023.					
427							
428	Figur	e legends:					
429							
430	Figur	e 1. Schematic process of literature review and screening.					
431							
432	Figur	e 2. Prior, likelihood, posterior distributions and corresponding 95% confidence					
433	interval.						
434							
435	Figur	e 3. Identification of Expanded GGCCTG Repeat within NOP56 in the SCA family					
436	pedigree. (A) The pedigree of a family with spinocerebellar ataxia 36. (B) Magnetic						
437	resonance imaging indicates cerebellar atrophy (white arrows) of II-2 and her corresponding						
438	conve	ntional PCR shows one peak in an allele and another a characteristic ladder pattern with					

- 439 a typical 6-bp periodicity repeat expansion in NOP56. (C) Long-read sequencing to ascertain
- the precise repeat range of II-2 and III-1.

tim	Year	• Ethnic group	Count	Pathogenic repeats	Mean age at onset (years)	Detection method	Reference
Garcia- Murias et al.	2012	Spain	27	650-2500	52.5 ± 7.2	Southern blot	[7]
Obayashi et al.	2014	French/ German/Japanese	17	21-2000	50.4±7.2	PCR- fragment analyses	[9]
Zou et al.	2023	Chinese	3	60-2023	44.5 ± 3.8	Long-read sequencing	[11]
Wang et al.	2022	Chinese	4	782 ~	$45 \pm /$	Long-read sequencing	[12]
Lee et al.	2016	Chinese	11	Not detected	44.8 ± 3.8	PCR- fragment analysis	[13]
Ikeda et al.	2012	Japanese	18	1700-2300	52.8 ± 4.3	Southern blot	[14]
Lam et al.	2022	British	7	30~	$48.4 \pm /$	Whole Genome Sequence	[15]
Valera et al.	2017	USA	6	1500~	44.5 ± 5.8	PCR- fragment analyses	[16]
Zeng et al.	2015	Chinese	14	1000~	50.82 ± 5.02	Southern blot	[17]

Table 1. Summary of 9 records with eligible data.





